Version July 2025
Dietary supplement: Oral: One tablet or capsule once daily at mealtime.
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
Refer to adult dosing.
Refer to individual vitamins for additional information.
Refer to individual vitamins for additional information.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Capsule, softgel, oral:
A&D Jr.: Vitamin A 10,000 units and vitamin D 400 units [contains soybean oil]
Generic: Vitamin A 1250 units and vitamin D 135 units, Vitamin A 5,000 units and vitamin D 400 units, Vitamin A 8,000 units and vitamin D 400 units
Oil, oral: Vitamin A 5000 units and vitamin D 500 units per 5 mL (120 mL, 473 mL)
Tablet, oral:
Generic: Vitamin A 10,000 units and vitamin D 400 units, Vitamin A 25,000 units and vitamin D 1000 units
Yes
Dietary supplement
Refer to individual components.
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.
Bexarotene (Topical): Vitamin A may increase adverse/toxic effects of Bexarotene (Topical). Management: Limit doses of vitamin A to 5,000 units per day if combined with topical bexarotene. Risk D: Consider Therapy Modification
Bile Acid Sequestrants: May decrease absorption of Vitamin D Analogs. Management: Consider separating administration of oral vitamin D analogs and bile acid sequestrants (BAS) to minimize the impact of this interaction. Give vitamin D analogs 1 to 4 hours before, or 4 to 6 hours after, BAS. Monitor for reduced vitamin D efficacy. Risk D: Consider Therapy Modification
Calcium Salts: May increase adverse/toxic effects of Vitamin D Analogs. Risk C: Monitor
Cardiac Glycosides: Vitamin D Analogs may increase arrhythmogenic effects of Cardiac Glycosides. Risk C: Monitor
Danazol: May increase hypercalcemic effects of Vitamin D Analogs. Risk C: Monitor
Erdafitinib: Serum Phosphate Level-Altering Agents may decrease therapeutic effects of Erdafitinib. Management: Avoid coadministration of serum phosphate level-altering agents with erdafitinib before initial dose increase period based on serum phosphate levels (Days 14 to 21). Risk D: Consider Therapy Modification
Mineral Oil: May decrease serum concentration of Vitamin D Analogs. More specifically, mineral oil may interfere with the absorption of Vitamin D Analogs. Management: Avoid concomitant, oral administration of mineral oil and vitamin D analogs. Consider separating the administration of these agents by several hours to minimize the risk of interaction. Monitor plasma calcium concentrations. Risk D: Consider Therapy Modification
Multivitamins/Fluoride (with ADE): May increase adverse/toxic effects of Vitamin D Analogs. Risk X: Avoid
Multivitamins/Minerals (with ADEK, Folate, Iron): May increase adverse/toxic effects of Vitamin D Analogs. Risk X: Avoid
Orlistat: May decrease absorption of Vitamins (Fat Soluble). Management: Administer oral fat soluble vitamins at least 2 hours before or 2 hours after the administration of orlistat. Avoid concomitant administration due to the risk of impaired vitamin absorption. Risk D: Consider Therapy Modification
Retinoic Acid Derivatives: Vitamin A may increase adverse/toxic effects of Retinoic Acid Derivatives. Risk X: Avoid
Thiazide and Thiazide-Like Diuretics: May increase hypercalcemic effects of Vitamin D Analogs. Risk C: Monitor
Refer to individual vitamins for additional information and specific requirements during pregnancy.
Refer to individual vitamins for additional information and specific requirements in nursing women.
